Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomitapide in familial chylomicronemia syndrome
2018-002911-80Phase 3Completed
- Sponsor
- Policlinico Paolo Giaccone
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lomitapide in primary chylomicronemia (FCS) and lipid disorder, sponsored by Policlinico Paolo Giaccone. Primary endpoint: Percent change in triglycerides. Started May 2020; status: completed.
02
Drugs
lomitapide
03
Conditions
primary chylomicronemia (FCS)lipid disorder
Beyond the preview
Go deeper on 2018-002911-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002911-80.